Mimetogen Initiates Dry Eye Disease Drug Study

24 November 2010 (Last Updated November 24th, 2010 18:30)

Mimetogen Pharmaceuticals has initiated a Phase II trial of MIM-D3, a mimetic of nerve growth factor, in patients with moderate to severe dry eye disease. Nerve growth factor is a protein that naturally occurs in the eye and is responsible for maintenance of the epithelium and corneal

Mimetogen Pharmaceuticals has initiated a Phase II trial of MIM-D3, a mimetic of nerve growth factor, in patients with moderate to severe dry eye disease.

Nerve growth factor is a protein that naturally occurs in the eye and is responsible for maintenance of the epithelium and corneal nerves, and tear production.

The randomised, double-masked, placebo-controlled and multicentre study will enrol 150 patients, and is designed to evaluate the safety, tolerability and efficacy of MIM-D3 in improving the symptoms of dry eye disease.

The chronic multifactorial condition can cause in visual disturbances and discomfort.